✦ LIBER ✦

A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer

✍ Scribed by J.D. WRIGHT; A.A. SECORD; T.M. NUMNUM; R.P. ROCCONI; M.A. POWELL; A. BERCHUCK; R.D. ALVAREZ; R.K. GIBB; K. TRINKAUS; J.S. RADER; D.G. MUTCH

Book ID: 109086228
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 145 KB
Volume: 18
Category: Article
ISSN: 1048-891X
DOI: 10.1111/j.1525-1438.2007.01027.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Factors predictive of toxicity associate

Factors predictive of toxicity associated with bevacizumab and chemotherapy in recurrent ovarian cancer: A multi-institutional study

✍ J. Chan; W. Huh; C. McClung; A. Alvarez-Secord; K. Moore; R. Previs; L. Perry; K 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Prognostic factors predictive of respons

Prognostic factors predictive of response to bevacizumab combined with chemotherapy in recurrent ovarian cancer – A multi-institutional study

✍ A. Alvarez-Secord; W. Huh; T. Tillmanns; K. Moore; J. Chapman; C. McClung; T. Ki 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 86 KB

The efficacy and safety of chemotherapy

The efficacy and safety of chemotherapy in combination with bevacizumab vs. bevacizumab alone in recurrent epithelial ovarian cancer – A multi-institutional study

✍ K. Fuh; A. Alvarez-Secord; W. Huh; T. Tillmanns; K. Moore; K. Bevis; A. ElNaggar 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 69 KB

Outcomes of ovarian cancer patients afte

Outcomes of ovarian cancer patients after bevacizumab and chemotherapy in primary vs. recurrent setting – A multi-institutional study

✍ J. Chan; A. Alvarez-Secord; T. Tillmanns; K. Moore; K. Bevis; A. ElNaggar; L. Pe 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 63 KB

Determining surrogate endpoints predicti

Determining surrogate endpoints predictive of overall survival in patients treated with bevacizumab for advanced ovarian cancer — A multi-institutional study

✍ S. Ueda; A. Alvarez-Secord; W. Huh; T. Tillmanns; K. Moore; R. Previs; L. Perry; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Trends of bevacizumab use and toxicity i

Trends of bevacizumab use and toxicity in advanced ovarian cancer over the last 7 years: A multi-institutional study

✍ J. Chapman; K. Fuh; A. Alvarez-Secord; W. Huh; T. Tillmanns; K. Moore; K. Bevis; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 64 KB